Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis COPD Drug Wil Test The LABA Safety Waters During Advisory Panel Review

This article was originally published in The Pink Sheet Daily

Executive Summary

Given the known risks of long-acting beta-2 agonists, a safety discussion seems likely when the Pulmonary-Allergy Drugs Advisory Committee meets to review Novartis' Arcapta Neohaler (indacaterol maleate).
Advertisement

Related Content

Novartis Resubmits Onbrez To FDA; Touts Comparative Trial Against Spiriva
LABA Safety Studies, REMS Are Next Topics For Sponsors, FDA After Relabeling
Clinical Trials Or Observational Studies For Asthma? FDA Advisory Panels Can't Agree
Clinical Trials Or Observational Studies For Asthma? FDA Advisory Panels Can't Agree
Despite European Nod, Novartis Gets FDA "Complete Response" For Indacaterol

Topics

Advertisement
UsernamePublicRestriction

Register

PS071700

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel